Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Carfilzomib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 31 May 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 18 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2018.